Last updated 2026-08-30
Total raised
—
Stage
—
Founded
2025
Headcount
5
HQ
Israel, Israel
Sector
Medical Devices
About
AptomixRX is developing first-in-class oral TNFα inhibitors based on a newly discovered binding pocket, combining AI-driven design and human organoid models to deliver safer, more effective therapies for autoimmune and inflammatory diseases.
Headcount over time
5 employees (2026-09) · 1 point
Offices
Israel, Israel · HQ / main office
Q&A
- What is AptomixRX's primary focus?
- AptomixRX is developing first-in-class oral TNFα inhibitors based on a newly discovered binding pocket, combining AI-driven design and human organoid models to deliver safer, more effective therapies for autoimmune and inflammatory diseases.
- When was AptomixRX founded?
- AptomixRX was founded in 2025.
- What sector does AptomixRX primarily operate in?
- AptomixRX's primary sector is Medical Devices.
- Where is AptomixRX headquartered?
- AptomixRX is headquartered in Israel.
- Who is a key contact for AptomixRX?
- Roger Kornberg is listed as a contact for AptomixRX.
- What technologies does AptomixRX utilize?
- AptomixRX utilizes Artificial intelligence and Pharma technologies.
- What are AptomixRX's target customers?
- AptomixRX's target customers are physicians.
Team · 1
Roger Kornberg
Founder · Contact Person
Sectors & technology
Primary sector
Medical Devices
Technologies
Target customers
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2025 |
|---|---|
| Employees (exact) | 5 |